Guss Grimmett
Nurse Practitioner · Blackfoot, IDNPI 1881620730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 34.6% of the total. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$356
- Novartis$164
- Abbott$158
- Axsome Therapeutics, Inc.$157
- GSK$128
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,183100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,103 |
| Lilly USA, LLC | 28 | $356 |
| Novartis | 8 | $164 |
| Abbott | 10 | $158 |
| Axsome Therapeutics, Inc. | 9 | $157 |
| GSK | 9 | $128 |
| Novo Nordisk | 8 | $127 |
| Phathom Pharmaceuticals, Inc. | 7 | $111 |
| Pfizer | 5 | $75 |
| Boehringer Ingelheim | 5 | $67 |
| Johnson & Johnson | 4 | $66 |
| Boston Scientific | 4 | $60 |
| Insulet Corporation | 2 | $56 |
| Corium, LLC | 8 | $54 |
| Amgen | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Astellas Pharma US Inc | 2 | $44 |
| Dexcom, Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 4 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| AstraZeneca | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Medtronic | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$3,183 in reported general payments places this provider in the 90th percentile of 570 nurse practitioner providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $201,836 |
| MounjaroTirzepatide | 199 | $199,486 |
| EliquisApixaban | 198 | $181,663 |
| XareltoRivaroxaban | 63 | $71,943 |
| TrulicityDulaglutide | 58 | $67,195 |
| RybelsusSemaglutide | 40 | $65,600 |
| JardianceEmpagliflozin | 42 | $36,444 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $35,690 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $35,596 |
| Nurtec OdtRimegepant Sulfate | 19 | $33,653 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $22,434 |
| JanuviaSitagliptin Phosphate | 19 | $21,859 |
| FarxigaDapagliflozin Propanediol | 22 | $20,541 |
| VraylarCariprazine Hcl | 15 | $20,471 |
| ZenpepLipase/Protease/Amylase | 16 | $18,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $127 | $267,436249 claims |
| Lilly USA, LLCMounjaro, Trulicity | $356 | $266,681257 claims |
| PfizerEliquis, Nurtec Odt | $75 | $215,317217 claims |
| Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat, Combivent Respimat | $67 | $75,767100 claims |
| Johnson & JohnsonXarelto | $66 | $71,94363 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $25 | $38,61267 claims |
| GSKTrelegy Ellipta | $128 | $35,59643 claims |
| AbbVieVraylar, Linzess | $1,103 | $33,08730 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $18,02935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 nurse practitioner providers in Idaho.
Other nurse practitioner in Blackfoot
- Kathleen CliffordBoise$119K
- Alissa HelvikCoeur D Alene$93K
- Amanda ThompsonIdaho Falls$67K
- Micalena PerkinsBurley$44K
- Tosha JohnsonNampa$26K
- Loreen NugentBoise$20K
- Rachel RyanMeridian$19K
- Stephanie HartPost Falls$18K
- Joshua ScovilleTwin Falls$12K
- John PilcherBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.